PIIS2666524722001902.pdf (51.96 kB)
Download file

Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it?

Download (51.96 kB)
journal contribution
posted on 12.09.2022, 15:08 authored by Patrick M. Meyer Sauteur, Victoria J. Chalker, Christoph Berger, Ran Nir-Paz, Mike BeetonMike Beeton, ESGMAC–MyCOVID Study Team

 Mycoplasma pneumoniae is a major bacterial cause of respiratory tract infection.1 We recently established a collaborative global network to assess the impact of non-pharmaceutical interventions (NPIs) against COVID-19 on transmission of M. pneumoniae. Data collected through this network showed significantly reduced M. pneumoniae incidence in the first year after implementation of NPIs (1 April 2020–31 March 2021) compared with previous years (2017–2020) (1.69% vs 8.61%),2 as observed for other respiratory infections.3 Lifting of NPIs has led to resurgence of many respiratory pathogens.4,5 Here, we used this network to track M. pneumoniae in the second year after implementation of NPIs (1 April 2021–31 March 2022), during which NPIs were relaxed or discontinued.  

History

Published in

The Lancet Microbe

Publisher

Elsevier

Version

VoR (Version of Record)

Citation

Sauteur, P.M.M., Chalker, V.J., Berger, C., Nir-Paz, R., Beeton, M.L., Pereyre, S., Bébéar, C., Wagner, N., Andreutti, C., Greub, G. and Agyeman, P.K.,(2020) 'Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it?',. The Lancet Microbe. DOI: 10.1016/S2666-5247(22)00190-2

Electronic ISSN

2666-5247

Cardiff Met Affiliation

Cardiff School of Sport and Health Sciences

Cardiff Met Authors

Mike Beeton

Cardiff Met Research Centre/Group

  • Microbiology & Infection

Copyright Holder

© The Publisher

Language

en